VEGFA and pancreatic neuroendocrine tumor: More recently, everolimus [35], a mechanistic target of rapamycin (mTOR) inhibitor, and sunitinib [36], an oral vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor, were approved by the US Food and Drug Administration (FDA) for the treatment of advanced pancreatic NETs in 2011 [31].